ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2033

Mortality Prognostic Factors Of Patients With Systemic Autoimmune Diseases Admitted To An Intensive Care Unit

Pamela Inés Doti1, Sara Fernandez2, Emmanuel Coloma3, Ona Escoda3, Ignasi Rodiguez-Pintó3, Pedro Castro2, Gerard Espinosa3 and José María Nicolás2, 1Department of Autoimmune Diseases, Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Spain, 2Medical Intensive Care Unit, Hospital Clínic, Barcelona, Barcelona, Spain, 3Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Spain

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Autoimmune diseases and intensive care

  • Tweet
  • Email
  • Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases II: Miscellaneous Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose: To identify mortality prognostic factors of patients with systemic autoimmune diseases (SAD) admitted in a medical intensive care unit (ICU).

Methods: Retrospective observational study including all patients with SAD admitted to a medical ICU of a tertiary referral centre between January 1999 and December 2012. Only patients with the diagnosis of SAD according to accepted criteria made prior to ICU admission or during hospitalization were selected. Patients with short term irreversible disease and those with an ICU stay less than 48 hours were excluded. The reason for ICU admission, clinical follow-up, immunosuppressive treatment received before ICU admission, and outcome were collected. Mortality prognostic factors were identified through logistic regression analysis. 

Results: Seventy patients accounting for 75 ICU admissions (48 [68.6%] women) with mean (SD) age of 54 (19.3) years were included. Five patients were admitted twice. Twenty-three (30.7%) patients had systemic lupus erythematosus (SLE) (mean SLE Disease Activity Index [SLEDAI] at ICU admission 8.2 (5.6) [range 0-20]); 23 (30.7%) had systemic vasculitis (mean Birmingham Vasculitis Activity Score [BVAS] 14.5 (9.3) [range 0-33]); 7 (9.3%) systemic sclerosis; 7 (9.3%) dermatomyositis, and 5 (6.7%) had Sjögren´s syndrome. The reasons for ICU admission were infection in 26 (34.7%), followed by autoimmune disease flare-up in 17 (22.7%). Other complications related or not with the SAD were present in 26 (34.7%) patients. The mean Acute Physiology and Chronic Health Evaluation (APACHE II) at admission was 16.5 (6.5) (range 5-31). At the end of follow-up, 29 (41.4%) patients had died, 10 (14.2%) during the stay at ICU, 7 (10%) during hospitalization, and 12 (17.1%) after hospital discharge. A logistic regression model showed that multiorgan failure (respiratory failure [p=0.032], renal failure [p=0.017]), and the need of renal replacement therapy [p=0.007] were risk factors associated with increased mortality. In addition, corticosteroid therapy [p<0.005] and the need of intravenous immunoglobulin treatment [p<0.005] during the stay at ICU, and the use of cyclophosphamide in the previous six months [p=0.016] of ICU admission, were also risk factors associated with increased mortality. 

Conclusion: The most prevalent SAD admitted to a medical ICU were SLE and systemic vasculitis being infections the main reason for admission. The presence of respiratory and renal failure, the need of renal replacement therapy, the need of corticosteroid or intravenous immunoglobulin during the stay in ICU and the use of cyclophosphamide before the admission were factors associated with increased risk of mortality.


Disclosure:

P. I. Doti,
None;

S. Fernandez,
None;

E. Coloma,
None;

O. Escoda,
None;

I. Rodiguez-Pintó,
None;

P. Castro,
None;

G. Espinosa,
None;

J. M. Nicolás,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mortality-prognostic-factors-of-patients-with-systemic-autoimmune-diseases-admitted-to-an-intensive-care-unit/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology